๋ก์ฟ ๋ก๋ ๋ธ๋ก๋ง์ด๋
๋ก์ฟ ๋ก๋ ๋ธ๋ก๋ง์ด๋๋ ์๋ฏธ๋ ธ์คํ ๋ก์ด๋๊ณ, ๊ฒฝ์์ , **๋นํ๋ถ๊ทน์ฑ ์ ๊ฒฝ๊ทผ ์ฐจ๋จ์ (NMBA)**์ ๋๋ค. ์ฃผ๋ก ์ ์ ๋ง์ทจ์ ๋ณด์กฐ์ ๋ก ์ฌ์ฉ๋์ด ์ ์ํ ๊ธฐ๊ด ๋ด ์ฝ๊ด์ ์ฉ์ดํ๊ฒ ํ๊ณ , ์ฌ์ธํ ์์ (์: ์๊ณผ, ์ ๊ฒฝ์ธ๊ณผ ๋๋ ํ๋ถ์ธ๊ณผ ์์ ) ์ค ๊น์ ๊ณจ๊ฒฉ๊ทผ ์ด์์ ์ ๊ณตํฉ๋๋ค. ์ฃผ์ ์ฝ๋ฆฌํ์ ํน์ง์ ๋ค์๊ณผ ๊ฐ์ต๋๋ค: * **๋น ๋ฅธ~์ค๊ฐ ์ ๋์ ๋ฐํ ์๊ฐ**: ๋ฒ ์ฟ ๋ก๋์ด๋ ์ํธ๋ผ์ฟ ๋ฅจ์ ๋นํด ์์ฉ ๋ฐํ์ด ๋น ๋ฅด๋ฉฐ(๋ฒ ์ฟ ๋ก๋๋ณด๋ค 2-3๋ฐฐ ๋น ๋ฆ), ์์๋์ฝ๋ฆฐ๊ณผ ๊ฑฐ์ ๋น์ทํ๊ฒ ๋น ๋ฅด์ง๋ง ๋ถ์์ฉ์ ๋ ์ ์ต๋๋ค. * **์ค๊ฐ ์ ๋์ ์์ฉ ์ง์ ์๊ฐ**: ๋ฒ ์ฟ ๋ก๋ ๋ฐ ์ํธ๋ผ์ฟ ๋ฅจ๊ณผ ์ ์ฌํ ์์ฉ ์๊ฐ์ ๊ฐ์ง๋๋ค. * **์ฌํ๊ด๊ณ ์์ ์ฑ**: ๊ธฐ์กด์ ์ ๊ฒฝ๊ทผ ์ฐจ๋จ์ ์ ๋นํด ์ฌํ๊ด๊ณ ๋ฐ ํ์คํ๋ฏผ ๋ถ๋น์ ๋ฏธ์น๋ ์ํฅ์ด ์ต์ํ๋์์ต๋๋ค. > **์์ ํต์ฌ ํฌ์ธํธ:** ๋ก์ฟ ๋ก๋๊ณผ ๊ฐ์ ์ ๊ฒฝ๊ทผ ์ฐจ๋จ์ ๋ **์งํต, ์ง์ ๋๋ ๊ธฐ์ต ์์ค ํจ๊ณผ๊ฐ ์ ํ ์์ต๋๋ค**. ์์์ด ์๊ฑฐ๋ ๋ง์ทจ๊ฐ ๋ถ์ถฉ๋ถํ ํ์์๊ฒ ํฌ์ฌํ๋ฉด ์์ ํ ๊นจ์ด ์๊ณ ํต์ฆ์ ๋๋ ์ ์๋ ์ํ์์ ์ ์ ์ด ๋ง๋น๋๋ ๋์ฐํ ๊ฒฝํ์ ์ด๋ํฉ๋๋ค. ๋ฐ๋ผ์ ๋ฐ๋์ ๊น๊ฒ ๋ง์ทจ๋์ด ์๊ณ ๊ธฐ๊ณ์ ํ๊ธฐ๊ฐ ์ฆ์ ๊ฐ๋ฅํ ํ์์๊ฒ๋ง ์ฌ์ฉํด์ผ ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Rocuronium acts by competitively antagonizing acetylcholine (ACh) at the neuromuscular junction. * **Mechanism**: It binds to **nicotinic cholinergic receptors** at the motor end plate of skeletal muscle. * **Pathway**: Rocuronium occupies the receptor site โ prevents ACh from binding โ inhibits depolarization of the muscle cell membrane โ results in flaccid paralysis. * **Reversal**: Because the blockade is competitive, it can be antagonized by increasing the concentration of ACh in the synaptic cleft. This is achieved using **acetylcholinesterase inhibitors** (e.g., neostigmine, edrophonium). Alternatively, rocuronium can be directly encapsulated and inactivated in the plasma by the selective relaxant binding agent **sugammadex**.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- As a neuromuscular blocker ยท 0.6 mg/kg IV ยท IV ยท Single dose ยท Rapid onset, short duration of action, and does not cause significant changes in heart rate.
- Neuromuscular blockade / Endotracheal intubation ยท 0.3-0.6 mg/kg i.v. ยท IV ยท Single dose ยท Approx 20 min at 0.6 mg/kg ยท 0.6 mg/kg has a rapid onset and short duration of action (20 min). Requires prompt successful intubation and ventilation.
- As a neuromuscular blocker ยท 0.6 mg/kg IV ยท IV ยท Single dose ยท Provided predictable blockade without hemodynamic changes, but large variation between individuals; monitoring of neuromuscular block is essential.
- As a neuromuscular blocker ยท 0.5 mg/kg bolus and then a CRI was started immediately at 0.2 mg/kg/hour ยท IV ยท Bolus followed by CRI ยท Authors concluded it was effective and easily applicable, but further work is required on infusion titration.
- Neuromuscular blockade during anaesthesia ยท 0.4 mg/kg i.v. followed, when required, by a maintenance dose of 0.16 mg/kg i.v. prn or continuous rate infusion of 0.2 mg/kg/h ยท IV ยท prn or CRI ยท As needed during surgery ยท Monitoring with a nerve stimulator is recommended.
- Centralize the globe for ophthalmic surgery ยท 0.05-0.1 mg/kg i.v. ยท IV ยท Single dose or prn ยท As needed ยท Considerably lower doses are required for this indication.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypersensitivity to rocuronium or other neuromuscular blocking agents
- Patients who are not adequately anesthetized or sedated
- Settings lacking immediate access to intubation, mechanical ventilation, and oxygen therapy
- Conscious or inadequately anaesthetized animals
- Lack of positive pressure ventilation facilities
์ด์๋ฐ์
- Changes in heart rate (mild, transient tachycardia)
- Changes in blood pressure (hypotension or hypertension)
- Severe anaphylaxis (reported in humans)
- Histaminoid reactions (rare)
- Severe burning pain at the injection site (if administered before deep anesthesia is achieved)
- Increased heart rate
- Mild hypertension (at high doses)
์ฝ๋ฌผ ์ํธ์์ฉ
- Other Non-depolarizing Muscle Relaxants ยท May have a synergistic effect if used concurrently with rocuronium.
- Succinylcholine ยท May speed the onset of action and enhance the neuromuscular blocking actions of rocuronium; do not give rocuronium until succinylcholine effects have subsided.
- Aminoglycosides (e.g., gentamicin, amikacin) ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Inhalant Anesthetics (halothane, isoflurane, sevoflurane) ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Clindamycin, Lincomycin ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Dantrolene ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Magnesium Salts ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Piperacillin, Mezlocillin ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Quinidine ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Tetracyclines ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Verapamil ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
๋ชจ๋ํฐ๋ง
- Degree of neuromuscular blockade (using a peripheral nerve stimulator/Train-of-Four monitor)
- Heart rate and rhythm
- Blood pressure
- Oxygenation (SpO2) and ventilation (End-tidal CO2)
- Depth of anesthesia
- Neuromuscular blockade depth (using a peripheral nerve stimulator)
- Heart rate and blood pressure
- Spontaneous respiratory effort during recovery
๊ณผ์ฉ๋
Overdosage with neuromuscular blocking agents results in **prolonged neuromuscular blockade** (extended paralysis). * **Primary Treatment**: Maintenance of a patent airway, continuous mechanical ventilation, oxygenation, and adequate sedation/anesthesia until full recovery of muscle function is assured. * **Reversal**: Only after spontaneous evidence of recovery is observed should administration of an anticholinesterase drug (e.g., neostigmine) combined with an anticholinergic agent (e.g., atropine or glycopyrrolate to prevent severe bradycardia) be considered. * **Specific Antidote**: Rocuronium's effects can be rapidly and specifically reversed by **sugammadex**, a cyclodextrin binding agent that encapsulates the drug in the plasma.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.